TM6SF2 and metabolic dysfunction-associated steatotic liver disease: This effect has been even confirmed by Xu and colleagues, which reported an interaction between the PNPLA3 p.I148M and TM6SF2 p.E167K variants in northeast China population, conferring an higher risk to develop NAFLD in patients carrying both mutations (OR: 5.133 in carriers of the p.I148M and p.E167K vs. OR: 1.91 in carriers of the p.I148M variant alone or OR: 3.62 in carriers of the p.E167K variant alone) [243].